tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Vistagen initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Vistagen (VTGN) with a Buy rating and $19 price target The company is developing the first drug, fasedienol, to treat social anxiety disorder episodically, when needed, the analyst tells investors in a research note. The firm views social anxiety disorder episodically as an underserved condition.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1